CAS-59-92-7

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

Pharma Deals, Investments and M&As in March 2018

If the first two months of 2018 saw pharma and biotech firms receive more money than what al

FDA announces generic drug user fees for FY18; Gilead acquires Kite for US$ 12 billion

This week, Phispers brings you the FY18 user fee schedule under GDUFA II, posted by the USFDA, with

GSK, Google form first bioelectronics firm; 11 generic companies benefit from the Teva Allergan deal

This week, Phispers brings to you the details of the bioelectronics firm formed by GSK and Google. T

Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?

 Over 700 commonly used generic medicines were recommended for suspension by the European Medic

Teva and Otsuka’s Multi-Billion dollar plan when blockbusters turn Generic: Deuterium Chemistry

Two blockbusters, Otsuka’s Abilify® (aripiprazole) and Teva’s Copaxone® (glatir